• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Down0.08% Nasdaq Up0.22%

    Oncothyreon Inc (ONTY)

    3.38 0.00(0.00%) Nov 27, 1:00PM EST
    ProfileGet Profile for:
    Oncothyreon Inc
    2601 Fourth Avenue
    Suite 500
    Seattle, WA 98121
    United States - Map
    Phone: 206-801-2100
    Fax: 206-801-2101
    Website: http://www.oncothyreon.com

    Index Membership:N/A
    Full Time Employees:49

    Business Summary 

    Oncothyreon Inc., a clinical-stage biopharmaceutical company, engages in the research and development of therapeutic products for the treatment of cancer. Its clinical-stage product candidates include ONT-380, an orally active and selective small-molecule HER2 inhibitor, which is in two Phase 1b trials, one in combination with Kadcyla and another in combination with Xeloda and/or Herceptin; and ONT-10, a therapeutic vaccine in Phase 1 trial targeting the Mucin 1 peptide antigen (MUC1) for use in various cancer indications, including breast, thyroid, colon, stomach, pancreas, ovarian, and prostate, as well as certain types of lung cancer. The company is also developing Checkpoint kinase 1, a protein kinase in pre-clinical studies to inhibit tumor growth as single agents. In addition, it focuses on researching on Protocells, which are nanoparticles designed to enable the targeted delivery of various therapeutic agents, including nucleic acids, proteins, peptides, and small molecules, as well as to develop product candidates for the treatment of cancer and rare diseases. The company has a research collaboration agreement with Sentinel Oncology Ltd. for the discovery of novel Chk1 inhibitors; collaboration with Celldex Therapeutics, Inc. on a combined clinical trial of ONT-10 and varlilumab; and collaboration with Adimab LLC for the discovery of novel antibodies against undisclosed immunotherapy targets in oncology. Oncothyreon Inc. was founded in 1985 and is headquartered in Seattle, Washington.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Oncothyreon Inc

    Corporate Governance 
    Oncothyreon Inc’s ISS Governance QuickScore as of Nov 1, 2015 is 8. The pillar scores are Audit: 2; Board: 8; Shareholder Rights: 8; Compensation: 7.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
    Dr. Robert L. Kirkman M.D., 66
    Chief Exec. Officer, Pres and Director
    Ms. Julia M. Eastland M.B.A., 51
    Chief Financial Officer, Principal Accounting Officer, VP of Corp. Devel. and Sec.
    Mr. Gary Christianson PE, 60
    Chief Operating Officer
    Dr. Scott Robert Peterson Ph.D., 53
    Chief Scientific Officer
    Dr. Diana F. Hausman M.D., 52
    Chief Medical Officer
    Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders